Purified Cortrophin® Gel for treating acute gout flares at two dose levels

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, multicenter study that compares a single subcutaneous or intramuscular injection of 40 U versus 80 U Purified Cortrophin® Gel in adults with acute gout flares. Patients are randomized 1:1 and followed with assessments at 24, 48, and 72 hours and again on Day 7 after dosing. Pain intensity and safety measures are collected at each visit to characterize short-term benefit and adverse effects. The study enrolls adults with recent-onset flares who are intolerant of or contraindicated for standard gout flare therapies such as NSAIDs or colchicine.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent to participate in this study
* Male and female patients, aged 18-85 years
* Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative
* Onset of current acute gout flare within 5 days prior to study entry
* Body mass index of less than or equal to 45 kg/m2
* Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)
* History of ≥ 1 gout flares within the 12 months prior to study entry
* The patient meets at least one of the following criteria for both NSAIDs and colchicine treatment options:
* Minimum of one episode of being intolerant, or unresponsive to the treatment, see Appendices 2-4.
* The investigator deems the patient is either contraindicated or inappropriate for the treatment. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication), see Appendices 2-4.
* Patients must be willing and capable of using an electronic device (e.g., cellphone) and must have access to a cellphone to be able to complete surveys.

Exclusion Criteria:

* Patients with scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, ocular herpes simplex, recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)), history of or the presence of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, uncontrolled diabetes type 1 or 2, or sensitivity to proteins derived from porcine sources.
* Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
* Rheumatoid arthritis, evidence or suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
* Polyarticular gouty arthritis involving more than 4 joints.
* Participation in another concurrent investigational study within 30 days of randomization or has taken an investigational drug within five times the half-life of that investigational drug has passed.
* Previous inclusion in this study.
* Presence of severe renal function impairment: estimated creatinine clearance \<30 mL/min/1.73m2 (CKD stages 4 and 5).
* Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.
* Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.
* Prior or current treatment with any ACTH product.
* Pregnant or nursing (lactating) women. Women of childbearing age are required to be using an acceptable method of contraception.
* Patients taking urate-lowering therapy had to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.
* Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor \[TNF\] inhibitors) within specified periods (see Appendix 5) prior to randomization.

  * Vaccination within 30 days prior to study enrollment and during the study period.

Where it's running

• Mass General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Hyon K Choi, MD, DrPH — Massachusetts General Hospital
• Study coordinator: Ana D Fernandes, MA
• Email: adfernandes@mgh.harvard.edu
• Phone: 617-643-2140

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dapansutrile tablets for treating acute gout flares

  This study is testing if dapansutrile tablets can help people with acute gout flares feel better compared to a placebo.

  Recruiting at 30 sites Phase 2/3 Olatec Therapeutics, Inc. · Birmingham, Alabama and 39 other locations · NCT05658575

• Dotinurad in gout patients who can’t tolerate XOI or failed uricase treatment

  This trial tests whether dotinurad can lower uric acid levels in adults with gout who can’t use certain standard medicines or have not benefited from uricase.

  Recruiting at 41 sites Phase 2 Crystalys Therapeutics · Birmingham, Alabama and 40 other locations · NCT07535034

• Orienting project on crystal deposits in gout, CPPD, and osteoarthritis

  This project will follow adults with gout or CPPD and people with osteoarthritis to see if crystal deposits in joints and blood vessels change over time and relate to treatments or heart problems.

  Recruiting I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Milan, Milano · NCT07504146

• Remote monitoring for gout in primary care

  This project will test a smartphone self-management app to help adults with gout and high urate levels manage their condition alongside GP follow-up.

  Recruiting Diakonhjemmet Hospital · Oslo · NCT07490522

• Digital Care for holistic health in older adults with diabetes and multiple conditions

  This study tests a digital care program to help adults 50+ with type 2 diabetes and other chronic diseases improve disease control, self-management, mood, and quality of life.

  Recruiting Chang Gung University of Science and Technology · New Taipei City, Wugu District · NCT07310849

• IV PRX-115 at different dose schedules, with or without methotrexate, versus placebo for adults with gout

  This trial will test whether IV PRX-115 given on different schedules, with or without low-dose methotrexate, can lower uric acid and be safe in adults whose gout is not controlled by standard urate-lowering drugs.

  Recruiting at 35 sites Phase 2 Protalix · Glendale, Arizona and 34 other locations · NCT07280156

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.